Ondřej Slabý

11.5k total citations · 2 hit papers
278 papers, 8.3k citations indexed

About

Ondřej Slabý is a scholar working on Cancer Research, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ondřej Slabý has authored 278 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 172 papers in Cancer Research, 148 papers in Molecular Biology and 50 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ondřej Slabý's work include MicroRNA in disease regulation (127 papers), Cancer-related molecular mechanisms research (106 papers) and Circular RNAs in diseases (79 papers). Ondřej Slabý is often cited by papers focused on MicroRNA in disease regulation (127 papers), Cancer-related molecular mechanisms research (106 papers) and Circular RNAs in diseases (79 papers). Ondřej Slabý collaborates with scholars based in Czechia, United States and Austria. Ondřej Slabý's co-authors include Marek Svoboda, Rostislav Vyzula, Jiří Šáňa, Jaroslav Michálek, Lenka Radová, Pavel Fabián, Adas Darinskas, Marius Strioga, Sowmya Viswanathan and Radek Lakomý and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and PLoS ONE.

In The Last Decade

Ondřej Slabý

259 papers receiving 8.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Same or Not the Same? Comparison of Adipose Tissue-Derived Versus Bone Marrow-Derived Mesenchymal Stem and Stromal Cells

2012 663 citations Ondřej Slabý et al. profile →
Altered Expression of miR-21, miR-31, miR-143 and miR-145 Is Related to Clinicopathologic Features of Colorectal Cancer

2007 589 citations Ondřej Slabý, Marek Svoboda et al. profile →

Peers

Countries citing papers authored by Ondřej Slabý

Since Specialization

Citations

This map shows the geographic impact of Ondřej Slabý's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ondřej Slabý with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ondřej Slabý more than expected).

Fields of papers citing papers by Ondřej Slabý

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ondřej Slabý. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ondřej Slabý. The network helps show where Ondřej Slabý may publish in the future.

Co-authorship network of co-authors of Ondřej Slabý

This figure shows the co-authorship network connecting the top 25 collaborators of Ondřej Slabý. A scholar is included among the top collaborators of Ondřej Slabý based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ondřej Slabý. Ondřej Slabý is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Combination of Urinary MiR-501 and MiR-335 With Current Clinical Diagnostic Parameters as Potential Predictive Factors of Prostate Biopsy Outcome 2023 ·Cancer Genomics & Proteomics ·Jaroslav Juráček, (unknown), Karolína Trachtová, (unknown), (unknown), Dominik A. Barth, Martin Pichler, Michal Staník, Ondřej Slabý	5
2	Spinal Metastasis in a Patient with Supratentorial Glioblastoma with Primitive Neuronal Component: A Case Report with Clinical and Molecular Evaluation 2023 ·Diagnostics ·Michal Hendrych, P. Solar, Markéta Hermanová, Ondřej Slabý, (unknown), (unknown), (unknown), (unknown), Tomáš Kazda, Petr Pospíšil, Radek Lakomý, Jan Chrastina, Jiří Šáňa, Radim Jančálek	4
3	PredictONCO: a web tool supporting decision-making in precision oncology by extending the bioinformatics predictions with advanced computing and machine learning 2023 ·Briefings in Bioinformatics ·Jan Štourač, (unknown), (unknown), Petra Pokorná, (unknown), Joan Planas-Iglesias, Stanislav Mazurenko, Gaspar Pinto, (unknown), Jaroslav Štěrba, Ondřej Slabý, Jiřı́ Damborský, David Bednář	3
4	CCL2/MCP-1, interleukin-8, and fractalkine/CXC3CL1: Potential biomarkers of epileptogenesis and pharmacoresistance in childhood epilepsy 2023 ·European Journal of Paediatric Neurology ·(unknown), (unknown), Hana Ošlejšková, Ondřej Slabý, Lenka Radová, Tomáš Loja, (unknown), (unknown), Milan Brázdil, (unknown)	12
5	Lack of Association between Epidermal Growth Factor or Its Receptor and Reflux Esophagitis, Barrett’s Esophagus, and Esophageal Adenocarcinoma: A Case-Control Study 2022 ·Disease Markers ·(unknown), (unknown), Zdeněk Kala, Zuzana Jirásková Zákostelská, (unknown), Lumír Kunovský, Radek Kroupa, Zdeněk Pavlovský, Břetislav Lipový, (unknown), Lýdie Izakovičová Hollá, Ondřej Urban, (unknown), Robert Lischke, Tomáš Haruštiak, (unknown), Vladimír Procházka, Ondřej Slabý, Petra Bořilová Linhartová	1
6	Small Non-Coding RNAs as New Biomarkers to Evaluate the Quality of the Embryo in the IVF Process 2022 ·Biomolecules ·(unknown), (unknown), Katarína Šoltýs, (unknown), (unknown), (unknown), Karolína Trachtová, (unknown), (unknown), Peter Urdzík, Mária Mareková, Ondřej Slabý, Miroslava Rabajdová	7
7	Kinetics of d-lactate and ischemia-modified albumin after abdominal aortic surgery and their ability to predict intestinal ischemia 2022 ·Clinical Biochemistry ·Marie Tomandlová, (unknown), Robert Staffa, (unknown), Tomáš Křivka, (unknown), Ondřej Slabý, (unknown), Robert Vlachovský, Lenka Radová, Josef Tomandl	3
8	A tissue miRNA expression pattern is associated with disease aggressiveness of localized prostate cancer 2022 ·The Prostate ·Jaroslav Juráček, (unknown), Michal Staník, (unknown), Karolína Trachtová, (unknown), (unknown), Dominik A. Barth, Martin Pichler, Ondřej Slabý	2
9	Polymorphism rs7079 in miR-31/-584 Binding Site in Angiotensinogen Gene Associates with Earlier Onset of Coronary Artery Disease in Central European Population 2022 ·Genes ·Jan Novák, (unknown), Renata Héžová, (unknown), Filip Zlámal, Ota Hlinomaz, (unknown), Miroslav Souček, Anna Vašků, Ondřej Slabý, Julie Bienertová Vašků	3
10	OCaMIR—A Noninvasive, Diagnostic Signature for Early-Stage Ovarian Cancer: A Multi-cohort Retrospective and Prospective Study 2021 ·Clinical Cancer Research ·Raju Kandimalla, Wei Wang, Fan Yu, Nianxin Zhou, Feng Gao, Monique A. Spillman, (unknown), Ondřej Slabý, Bodour Salhia, Shengtao Zhou, Xin Wang, Ajay Goel	17
11	Pro-Inflammatory and Neurotrophic Factor Responses of Cells Derived from Degenerative Human Intervertebral Discs to the Opportunistic Pathogen Cutibacterium acnes 2021 ·International Journal of Molecular Sciences ·(unknown), Anna Konieczna, Andrew McDowell, Filip Růžička, Martin Smrčka, Radim Jančálek, (unknown), (unknown), Fahad Shabbir Ahmed, Christof Birkenmaier, Stefan Dudli, Ondřej Slabý	18
12	Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database 2019 ·Urologic Oncology Seminars and Original Investigations ·Alexandr Poprach, (unknown), Radek Lakomý, (unknown), Michal Staník, (unknown), Igor Kišš, Ondřej Slabý, Hana Študentová, Bohuslav Melichar, Jaroslav Juráček, Ondřej Fiala, Jindřich Kopecký, Kateřina Kopečková, Milada Zemanová, Tomáš Büchler	5
13	Exercise-induced circulating microRNA changes in athletes in various training scenarios 2018 ·PLoS ONE ·(unknown), Filip Zlámal, Robert Iliev, Jan Kučera, Jan Cacek, (unknown), (unknown), (unknown), Ondřej Slabý, Julie Bienertová Vašků	48
14	Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer 2017 ·Clinical Genitourinary Cancer ·Tomáš Büchler, Alexandr Poprach, Zbyněk Bortlíček, Radek Lakomý, (unknown), Rostislav Vyzula, Milada Zemanová, Kateřina Kopečková, Marek Svoboda, Ondřej Slabý, Igor Kišš, Hana Študentová, (unknown), Ondřej Fiala, Jindřich Kopecký, Jindřich Fínek, Ladislav Dušek, Bohuslav Melichar	8
15	Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry 2017 ·BMC Cancer ·Radek Lakomý, Alexandr Poprach, Zbyněk Bortlíček, Bohuslav Melichar, (unknown), Rostislav Vyzula, Milada Zemanová, Kateřina Kopečková, Marek Svoboda, Ondřej Slabý, Igor Kišš, Hana Študentová, Jaroslav Juráček, Ondřej Fiala, Jindřich Kopecký, Jindřich Fínek, Ladislav Dušek, Karel Hejduk, Tomáš Büchler	9
16	Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis 2016 ·Clinical Cancer Research ·Martin Pichler, Verena Stiegelbauer, Petra Vychytilova‐Faltejskova, Cristina Ivan, Hui Ling, Elke Winter, Xinna Zhang, (unknown), Annika Wulf-Goldenberg, Masahisa Ohtsuka, Johannes Haybaeck, Marek Svoboda, Yoshinaga Okugawa, Armin Gerger, Gerald Höefler, Ajay Goel, Ondřej Slabý, George A. Călin	61
17	Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy 2016 ·SHILAP Revista de lepidopterología ·Radim Němeček, (unknown), Lenka Radová, Tomáš Kazda, Jitka Mlčochová, Petra Vychytilova‐Faltejskova, Ondřej Slabý, Marek Svoboda	2
18	Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice 2016 ·Drugs & Aging ·(unknown), Alexandr Poprach, Radek Lakomý, Zbyněk Bortlíček, Bohuslav Melichar, Tomáš Pavlík, Ondřej Slabý, Rostislav Vyzula, Marek Svoboda, Igor Kišš, Hana Študentová, Milada Zemanová, Ondřej Fiala, Kateřina Kubáčková, Ladislav Dušek, (unknown), Tomáš Büchler	15
19	Výsledky multimodální léčby glioblastoma multiforme:konsekutivní série 86 pacientů diagnostikovaných v letech2003–2009 2011 ·Klinicka onkologie ·Radek Lakomý, Pavel Fadrus, Pavel Šlampa, Tomáš Svoboda, Leoš Křen, (unknown), (unknown), (unknown), Alexandr Poprach, (unknown), (unknown), Jiří Šáňa, Ondřej Slabý, Martin Smrčka, Rostislav Vyzula, Marek Svoboda	1
20	Brain metastases in breast cancer: a retrospective cohort studyof 187 patients and prognostic markers determination. 2007 ·Breast Cancer Research and Treatment ·Marek Svoboda, Pavel Fabián, (unknown), Markéta Palácová, (unknown), (unknown), (unknown), Ondřej Slabý, Pavel Šlampa, Rostislav Vyzula	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact